Successful canakinumab treatment for activated innate response in idiopathic Castleman's disease with multiple heterozygous MEFV exon 2 variants

Successful canakinumab treatment for activated innate response in idiopathic Castleman's disease with multiple heterozygous MEFV exon 2 variants

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 219(2020) vom: 30. Okt., Seite 108547
1. Verfasser: Endo, Yushiro (VerfasserIn)
Weitere Verfasser: Koga, Tomohiro, Umeda, Masataka, Furukawa, Kaori, Takenaka, Motoi, Kawakami, Atsushi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Case Reports Letter Research Support, Non-U.S. Gov't Canakinumab Castleman's disease Familial Mediterranean fever IL-1 inhibitors Antibodies, Monoclonal, Humanized Interleukin-1beta MEFV protein, human mehr... Pyrin canakinumab 37CQ2C7X93
Beschreibung
Beschreibung:Date Completed 17.05.2021
Date Revised 17.05.2021
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2020.108547